Sean Studer
Brooklyn, NYNPI 1851366710
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $158,290 of the $194,178 with a category attached, or 81.5%. 6 manufacturers reported payments, led by Actelion Pharmaceuticals US, Inc. at 57.1% of the total. Reporting peaked in 2019 at $142,038 and has fallen 100.0% since, to $54 in 2025.
Across 207 payments — averaging $938.06 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Actelion Pharmaceuticals US, Inc.$111K
- Insmed, Inc.$41K
- United Therapeutics Corporation$22K
- Genentech USA, Inc.$20K
- Boston Scientific$66
- Pfizer$31
What the payments were for
- Consulting fees$7,4104%
- Speaking & faculty fees$158,29082%
- Travel & lodging$23,71112%
- Food & beverage$4,6672%
- Education$1000%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Actelion Pharmaceuticals US, Inc. | 102 | $110,954 |
| Insmed, Inc. | 51 | $40,529 |
| United Therapeutics Corporation | 29 | $22,460 |
| Genentech USA, Inc. | 21 | $20,137 |
| Boston Scientific | 3 | $66 |
| Pfizer | 1 | $31 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.